{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:27:46Z","timestamp":1790458066010,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY027749"],"award-info":[{"award-number":["R01EY027749"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R24EY028764"],"award-info":[{"award-number":["R24EY028764"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R43EY031238"],"award-info":[{"award-number":["R43EY031238"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R43EY032827"],"award-info":[{"award-number":["R43EY032827"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R41EY027665"],"award-info":[{"award-number":["R41EY027665"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00109-022-02195-2","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:02:58Z","timestamp":1649419378000},"page":"817-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Neurovascular abnormalities in retinopathy of prematurity and emerging therapies"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-883X","authenticated-orcid":false,"given":"Chang","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8764","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4820-6537","authenticated-orcid":false,"given":"Guanfang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"2195_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","volume":"122","author":"ME Hartnett","year":"2015","unstructured":"Hartnett ME (2015) Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity. Ophthalmology 122:200\u2013210. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.050","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"2195_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe H, Lawn JE, Vazquez T et al (2013) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res 74(Suppl 1):35\u201349. https:\/\/doi.org\/10.1038\/pr.2013.205","journal-title":"Pediatr Res"},{"key":"2195_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F et al (2014) Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity. Ophthalmology 121:2212\u20132219. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015","journal-title":"Ophthalmology"},{"key":"2195_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ophtha.2017.09.020","volume":"125","author":"RN Vogel","year":"2018","unstructured":"Vogel RN, Strampe M, Fagbemi OE et al (2018) Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmology 125:444\u2013452. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.020","journal-title":"Ophthalmology"},{"key":"2195_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaapos.2017.06.024","volume":"21","author":"A Clark","year":"2017","unstructured":"Clark A, Wright T, Isaac M et al (2017) Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study. J AAPOS 21:499\u2013501.e1. https:\/\/doi.org\/10.1016\/j.jaapos.2017.06.024","journal-title":"J AAPOS"},{"key":"2195_CR6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"W-C Wu","year":"2017","unstructured":"Wu W-C, Shih C-P, Lien R et al (2017) SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY. Retina 37:694\u2013701. https:\/\/doi.org\/10.1097\/IAE.0000000000001209","journal-title":"Retina"},{"key":"2195_CR7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics 137:e20153218. https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"},{"key":"2195_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1542\/peds.109.1.12","volume":"109","author":"AR O\u2019Connor","year":"2002","unstructured":"O\u2019Connor AR, Stephenson T, Johnson A et al (2002) Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 109:12\u201318. https:\/\/doi.org\/10.1542\/peds.109.1.12","journal-title":"Pediatrics"},{"key":"2195_CR9","first-page":"257","volume":"26","author":"OJ Mezu-Ndubuisi","year":"2020","unstructured":"Mezu-Ndubuisi OJ, Macke EL, Kalavacherla R et al (2020) Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy. Mol Vis 26:257\u2013276","journal-title":"Mol Vis"},{"key":"2195_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2014.06.003","volume":"42","author":"M Hoon","year":"2014","unstructured":"Hoon M, Okawa H, Della Santina L, Wong ROL (2014) Functional architecture of the retina: development and disease. Prog Retin Eye Res 42:44\u201384. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.06.003","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","volume":"25","author":"A Bringmann","year":"2006","unstructured":"Bringmann A, Pannicke T, Grosche J et al (2006) M\u00fcller cells in the healthy and diseased retina. Prog Retin Eye Res 25:397\u2013424. https:\/\/doi.org\/10.1016\/j.preteyeres.2006.05.003","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/s1350-9462(01)00012-x","volume":"20","author":"JM Provis","year":"2001","unstructured":"Provis JM (2001) Development of the primate retinal vasculature. Prog Retin Eye Res 20:799\u2013821. https:\/\/doi.org\/10.1016\/s1350-9462(01)00012-x","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.001","volume":"63","author":"S Selvam","year":"2018","unstructured":"Selvam S, Kumar T, Fruttiger M (2018) Retinal vasculature development in health and disease. Prog Retin Eye Res 63:1\u201319. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.11.001","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR14","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood-2012-04-396846","volume":"120","author":"P Sapieha","year":"2012","unstructured":"Sapieha P (2012) Eyeing central neurons in vascular growth and reparative angiogenesis. Blood 120:2182\u20132194. https:\/\/doi.org\/10.1182\/blood-2012-04-396846","journal-title":"Blood"},{"key":"2195_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.preteyeres.2017.10.001","volume":"62","author":"GA Lutty","year":"2018","unstructured":"Lutty GA, McLeod DS (2018) Development of the hyaloid, choroidal and retinal vasculatures in the fetal human eye. Prog Retin Eye Res 62:58\u201376. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.10.001","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0008-6363(00)00084-5","volume":"47","author":"P Hardy","year":"2000","unstructured":"Hardy P (2000) Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res 47:489\u2013509. https:\/\/doi.org\/10.1016\/S0008-6363(00)00084-5","journal-title":"Cardiovasc Res"},{"key":"2195_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamaophthalmol.2013.5052","volume":"131","author":"W-C Wu","year":"2013","unstructured":"Wu W-C, Shih C-P, Wang N-K et al (2013) Choroidal thickness in patients with a history of retinopathy of prematurity. JAMA Ophthalmol 131:1451\u20131458. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.5052","journal-title":"JAMA Ophthalmol"},{"key":"2195_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/IAE.0000000000000866","volume":"36","author":"MK Erol","year":"2016","unstructured":"Erol MK, Coban DT, Ozdemir O et al (2016) CHOROIDAL THICKNESS IN INFANTS WITH RETINOPATHY OF PREMATURITY. Retina 36:1191\u20131198. https:\/\/doi.org\/10.1097\/IAE.0000000000000866","journal-title":"Retina"},{"key":"2195_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/eye.2014.207","volume":"28","author":"MF Anderson","year":"2014","unstructured":"Anderson MF, Ramasamy B, Lythgoe DT, Clark D (2014) Choroidal thickness in regressed retinopathy of prematurity. Eye (Lond) 28:1461\u20131468. https:\/\/doi.org\/10.1038\/eye.2014.207","journal-title":"Eye (Lond)"},{"key":"2195_CR20","doi-asserted-by":"publisher","first-page":"6548","DOI":"10.1167\/iovs.16-20128","volume":"57","author":"A Fie\u00df","year":"2016","unstructured":"Fie\u00df A, Christian L, K\u00f6lb-Keerl R et al (2016) Peripapillary choroidal thickness in former preterm and full-term infants aged from 4 to 10 years. Invest Ophthalmol Vis Sci 57:6548\u20136553. https:\/\/doi.org\/10.1167\/iovs.16-20128","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5301\/ejo.5000843","volume":"27","author":"IS Muslubas","year":"2017","unstructured":"Muslubas IS, Karacorlu M, Hocaoglu M et al (2017) Retinal and choroidal thickness in children with a history of retinopathy of prematurity and transscleral diode laser treatment. Eur J Ophthalmol 27:190\u2013195. https:\/\/doi.org\/10.5301\/ejo.5000843","journal-title":"Eur J Ophthalmol"},{"key":"2195_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ydbio.2011.12.027","volume":"363","author":"A Nakamura-Ishizu","year":"2012","unstructured":"Nakamura-Ishizu A, Kurihara T, Okuno Y et al (2012) The formation of an angiogenic astrocyte template is regulated by the neuroretina in a HIF-1-dependent manner. Dev Biol 363:106\u2013114. https:\/\/doi.org\/10.1016\/j.ydbio.2011.12.027","journal-title":"Dev Biol"},{"key":"2195_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/glia.23189","volume":"65","author":"ML O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan ML, Pu\u00f1al VM, Kerstein PC et al (2017) Astrocytes follow ganglion cell axons to establish an angiogenic template during retinal development. Glia 65:1697\u20131716. https:\/\/doi.org\/10.1002\/glia.23189","journal-title":"Glia"},{"key":"2195_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.exer.2011.12.005","volume":"96","author":"MM Edwards","year":"2012","unstructured":"Edwards MM, McLeod DS, Li R et al (2012) The deletion of Math5 disrupts retinal blood vessel and glial development in mice. Exp Eye Res 96:147\u2013156. https:\/\/doi.org\/10.1016\/j.exer.2011.12.005","journal-title":"Exp Eye Res"},{"key":"2195_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1101\/gad.2042011","volume":"25","author":"J Kim","year":"2011","unstructured":"Kim J, Oh W-J, Gaiano N et al (2011) Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev 25:1399\u20131411. https:\/\/doi.org\/10.1101\/gad.2042011","journal-title":"Genes Dev"},{"key":"2195_CR26","first-page":"3500","volume":"43","author":"MI Dorrell","year":"2002","unstructured":"Dorrell MI, Aguilar E, Friedlander M (2002) Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci 43:3500\u20133510","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR27","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","volume":"15","author":"J Stone","year":"1995","unstructured":"Stone J, Itin A, Alon T et al (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738\u20134747. https:\/\/doi.org\/10.1523\/JNEUROSCI.15-07-04738.1995","journal-title":"J Neurosci"},{"key":"2195_CR28","doi-asserted-by":"publisher","first-page":"17608","DOI":"10.1038\/s41598-017-17962-2","volume":"7","author":"L-J Duan","year":"2017","unstructured":"Duan L-J, Pan SJ, Sato TN, Fong G-H (2017) Retinal Angiogenesis Regulates Astrocytic Differentiation in Neonatal Mouse Retinas by Oxygen Dependent Mechanisms. Sci Rep 7:17608. https:\/\/doi.org\/10.1038\/s41598-017-17962-2","journal-title":"Sci Rep"},{"key":"2195_CR29","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.celrep.2016.10.035","volume":"17","author":"C Tao","year":"2016","unstructured":"Tao C, Zhang X (2016) Retinal Proteoglycans Act as Cellular Receptors for Basement Membrane Assembly to Control Astrocyte Migration and Angiogenesis. Cell Rep 17:1832\u20131844. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.035","journal-title":"Cell Rep"},{"key":"2195_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011863","volume":"5","author":"A Scott","year":"2010","unstructured":"Scott A, Powner MB, Gandhi P et al (2010) Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PLoS ONE 5:e11863. https:\/\/doi.org\/10.1371\/journal.pone.0011863","journal-title":"PLoS ONE"},{"key":"2195_CR31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/glia.20997","volume":"58","author":"A Weidemann","year":"2010","unstructured":"Weidemann A, Krohne TU, Aguilar E et al (2010) Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 58:1177\u20131185. https:\/\/doi.org\/10.1002\/glia.20997","journal-title":"Glia"},{"key":"2195_CR32","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1172\/JCI126655","volume":"129","author":"A Rattner","year":"2019","unstructured":"Rattner A, Williams J, Nathans J (2019) Roles of HIFs and VEGF in angiogenesis in the retina and brain. J Clin Invest 129:3807\u20133820. https:\/\/doi.org\/10.1172\/JCI126655","journal-title":"J Clin Invest"},{"key":"2195_CR33","doi-asserted-by":"publisher","unstructured":"Duan L-J, Takeda K, Fong G-H (2014) Hypoxia inducible factor-2\u03b1 regulates the development of retinal astrocytic network by maintaining adequate supply of astrocyte progenitors. PLoS One\u00a09:e84736.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0084736","DOI":"10.1371\/journal.pone.0084736"},{"key":"2195_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.trsl.2018.12.006","volume":"207","author":"X Li","year":"2019","unstructured":"Li X, Liu J, Hoh J, Liu J (2019) M\u00fcller cells in pathological retinal angiogenesis. Transl Res 207:96\u2013106. https:\/\/doi.org\/10.1016\/j.trsl.2018.12.006","journal-title":"Transl Res"},{"key":"2195_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/path.2611","volume":"219","author":"Y Bai","year":"2009","unstructured":"Bai Y, Ma J, Guo J et al (2009) M\u00fcller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol 219:446\u2013454. https:\/\/doi.org\/10.1002\/path.2611","journal-title":"J Pathol"},{"key":"2195_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0306-4522(93)90473-s","volume":"55","author":"S Tout","year":"1993","unstructured":"Tout S, Chan-Ling T, Holl\u00e4nder H, Stone J (1993) The role of M\u00fcller cells in the formation of the blood-retinal barrier. Neuroscience 55:291\u2013301. https:\/\/doi.org\/10.1016\/0306-4522(93)90473-s","journal-title":"Neuroscience"},{"key":"2195_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1742-2094-8-120","volume":"8","author":"F Fischer","year":"2011","unstructured":"Fischer F, Martin G, Agostini HT (2011) Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy. J Neuroinflammation 8:120. https:\/\/doi.org\/10.1186\/1742-2094-8-120","journal-title":"J Neuroinflammation"},{"key":"2195_CR38","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1167\/iovs.05-1522","volume":"47","author":"D Checchin","year":"2006","unstructured":"Checchin D, Sennlaub F, Levavasseur E et al (2006) Potential role of microglia in retinal blood vessel formation. Invest Ophthalmol Vis Sci 47:3595\u20133602. https:\/\/doi.org\/10.1167\/iovs.05-1522","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR39","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.3390\/ijms22094809","volume":"22","author":"C Dai","year":"2021","unstructured":"Dai C, Webster KA, Bhatt A et al (2021) Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. Int J Mol Sci 22:4809. https:\/\/doi.org\/10.3390\/ijms22094809","journal-title":"Int J Mol Sci"},{"key":"2195_CR40","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101\u2013111","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1203\/00006450-199412000-00007","volume":"36","author":"JS Penn","year":"1994","unstructured":"Penn JS, Henry MM, Tolman BL (1994) Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 36:724\u2013731. https:\/\/doi.org\/10.1203\/00006450-199412000-00007","journal-title":"Pediatr Res"},{"key":"2195_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/glia.20900","volume":"58","author":"MI Dorrell","year":"2010","unstructured":"Dorrell MI, Aguilar E, Jacobson R et al (2010) Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia 58:43\u201354. https:\/\/doi.org\/10.1002\/glia.20900","journal-title":"Glia"},{"key":"2195_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10633-009-9193-6","volume":"120","author":"EL Fletcher","year":"2010","unstructured":"Fletcher EL, Downie LE, Hatzopoulos K et al (2010) The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol 120:67\u201386. https:\/\/doi.org\/10.1007\/s10633-009-9193-6","journal-title":"Doc Ophthalmol"},{"key":"2195_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.exer.2017.12.007","volume":"168","author":"A Nakano","year":"2018","unstructured":"Nakano A, Asano D, Kondo R et al (2018) Retinal neuronal cell loss prevents abnormal retinal vascular growth in a rat model of retinopathy of prematurity. Exp Eye Res 168:115\u2013127. https:\/\/doi.org\/10.1016\/j.exer.2017.12.007","journal-title":"Exp Eye Res"},{"key":"2195_CR45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1167\/iovs.08-1920","volume":"50","author":"C Yang","year":"2009","unstructured":"Yang C, Lafleur J, Mwaikambo BR et al (2009) The role of lysophosphatidic acid receptor (LPA1) in the oxygen-induced retinal ganglion cell degeneration. Invest Ophthalmol Vis Sci 50:1290\u20131298. https:\/\/doi.org\/10.1167\/iovs.08-1920","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/path.2858","volume":"224","author":"V Sivakumar","year":"2011","unstructured":"Sivakumar V, Foulds WS, Luu CD et al (2011) Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina. J Pathol 224:245\u2013260. https:\/\/doi.org\/10.1002\/path.2858","journal-title":"J Pathol"},{"key":"2195_CR47","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1167\/iovs.13-13718","volume":"55","author":"G Rathnasamy","year":"2014","unstructured":"Rathnasamy G, Sivakumar V, Rangarajan P et al (2014) NF-\u03baB-mediated nitric oxide production and activation of caspase-3 cause retinal ganglion cell death in the hypoxic neonatal retina. Invest Ophthalmol Vis Sci 55:5878\u20135889. https:\/\/doi.org\/10.1167\/iovs.13-13718","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR48","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nm.1873","volume":"14","author":"P Sapieha","year":"2008","unstructured":"Sapieha P, Sirinyan M, Hamel D et al (2008) The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 14:1067\u20131076. https:\/\/doi.org\/10.1038\/nm.1873","journal-title":"Nat Med"},{"key":"2195_CR49","doi-asserted-by":"publisher","unstructured":"Sun Y, Ju M, Lin Z et al (2015) SOCS3 in retinal neurons and glial cells suppresses VEGF signaling to prevent pathological neovascular growth. Sci Signal 8:ra94. https:\/\/doi.org\/10.1126\/scisignal.aaa8695","DOI":"10.1126\/scisignal.aaa8695"},{"key":"2195_CR50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mcn.2013.06.001","volume":"56","author":"F Bucher","year":"2013","unstructured":"Bucher F, Stahl A, Agostini HT, Martin G (2013) Hyperoxia causes reduced density of retinal astrocytes in the central avascular zone in the mouse model of oxygen-induced retinopathy. Mol Cell Neurosci 56:225\u2013233. https:\/\/doi.org\/10.1016\/j.mcn.2013.06.001","journal-title":"Mol Cell Neurosci"},{"key":"2195_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00441-019-03112-9","volume":"379","author":"A Nakano","year":"2020","unstructured":"Nakano A, Kondo R, Kaneko Y et al (2020) Changes in components of the neurovascular unit in the retina in a rat model of retinopathy of prematurity. Cell Tissue Res 379:473\u2013486. https:\/\/doi.org\/10.1007\/s00441-019-03112-9","journal-title":"Cell Tissue Res"},{"key":"2195_CR52","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/archopht.1996.01100140410008","volume":"114","author":"CK Dorey","year":"1996","unstructured":"Dorey CK, Aouididi S, Reynaud X et al (1996) Correlation of vascular permeability factor\/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol 114:1210\u20131217. https:\/\/doi.org\/10.1001\/archopht.1996.01100140410008","journal-title":"Arch Ophthalmol"},{"key":"2195_CR53","doi-asserted-by":"publisher","first-page":"E3425","DOI":"10.1073\/pnas.1217091110","volume":"110","author":"X Xin","year":"2013","unstructured":"Xin X, Rodrigues M, Umapathi M et al (2013) Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4. Proc Natl Acad Sci U S A 110:E3425-3434. https:\/\/doi.org\/10.1073\/pnas.1217091110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2195_CR54","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s00125-011-2081-0","volume":"54","author":"M Lin","year":"2011","unstructured":"Lin M, Chen Y, Jin J et al (2011) Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal M\u00fcller cells. Diabetologia 54:1554\u20131566. https:\/\/doi.org\/10.1007\/s00125-011-2081-0","journal-title":"Diabetologia"},{"key":"2195_CR55","doi-asserted-by":"publisher","first-page":"8614","DOI":"10.1167\/iovs.14-15693","volume":"55","author":"A Rattner","year":"2014","unstructured":"Rattner A, Wang Y, Zhou Y et al (2014) The role of the hypoxia response in shaping retinal vascular development in the absence of Norrin\/Frizzled4 signaling. Invest Ophthalmol Vis Sci 55:8614\u20138625. https:\/\/doi.org\/10.1167\/iovs.14-15693","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR56","doi-asserted-by":"publisher","first-page":"E3030","DOI":"10.1073\/pnas.1423765112","volume":"112","author":"S Babapoor-Farrokhran","year":"2015","unstructured":"Babapoor-Farrokhran S, Jee K, Puchner B et al (2015) Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. Proc Natl Acad Sci U S A 112:E3030-3039. https:\/\/doi.org\/10.1073\/pnas.1423765112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2195_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12473","volume":"64","author":"Y Xu","year":"2018","unstructured":"Xu Y, Lu X, Hu Y et al (2018) Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1\u03b1-VEGF pathway in oxygen-induced retinopathy mice. J Pineal Res 64:e12473. https:\/\/doi.org\/10.1111\/jpi.12473","journal-title":"J Pineal Res"},{"key":"2195_CR58","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1161\/ATVBAHA.113.301331","volume":"33","author":"JC Rivera","year":"2013","unstructured":"Rivera JC, Sitaras N, Noueihed B et al (2013) Microglia and interleukin-1\u03b2 in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. Arterioscler Thromb Vasc Biol 33:1881\u20131891. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301331","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2195_CR59","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1161\/ATVBAHA.115.307080","volume":"36","author":"DM Talia","year":"2016","unstructured":"Talia DM, Deliyanti D, Agrotis A, Wilkinson-Berka JL (2016) Inhibition of the Nuclear Receptor ROR\u03b3 and Interleukin-17A Suppresses Neovascular Retinopathy: Involvement of Immunocompetent Microglia. Arterioscler Thromb Vasc Biol 36:1186\u20131196. https:\/\/doi.org\/10.1161\/ATVBAHA.115.307080","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2195_CR60","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.omtn.2019.04.029","volume":"16","author":"W Xu","year":"2019","unstructured":"Xu W, Wu Y, Hu Z et al (2019) Exosomes from Microglia Attenuate Photoreceptor Injury and Neovascularization in an Animal Model of Retinopathy of Prematurity. Mol Ther Nucleic Acids 16:778\u2013790. https:\/\/doi.org\/10.1016\/j.omtn.2019.04.029","journal-title":"Mol Ther Nucleic Acids"},{"key":"2195_CR61","unstructured":"Fu Y (1995) Phototransduction in Rods and Cones. In: Kolb H, Fernandez E, Nelson R (eds) Webvision: The Organization of the Retina and Visual System. University of Utah Health Sciences Center, Salt Lake City (UT)"},{"key":"2195_CR62","doi-asserted-by":"publisher","unstructured":"Fu Z, L\u00f6fqvist CA, Liegl R et al (2018) Photoreceptor glucose metabolism determines normal retinal vascular growth. EMBO Mol Med 10:76\u201390. https:\/\/doi.org\/10.15252\/emmm.201707966","DOI":"10.15252\/emmm.201707966"},{"key":"2195_CR63","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.preteyeres.2009.06.003","volume":"28","author":"AB Fulton","year":"2009","unstructured":"Fulton AB, Hansen RM, Moskowitz A, Akula JD (2009) The neurovascular retina in retinopathy of prematurity. Prog Retin Eye Res 28:452\u2013482. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.06.003","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR64","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1167\/iovs.07-1226","volume":"49","author":"AB Fulton","year":"2008","unstructured":"Fulton AB, Hansen RM, Moskowitz A (2008) The cone electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 49:814\u2013819. https:\/\/doi.org\/10.1167\/iovs.07-1226","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/archopht.119.4.499","volume":"119","author":"AB Fulton","year":"2001","unstructured":"Fulton AB, Hansen RM, Petersen RA, Vanderveen DK (2001) The rod photoreceptors in retinopathy of prematurity: an electroretinographic study. Arch Ophthalmol 119:499\u2013505. https:\/\/doi.org\/10.1001\/archopht.119.4.499","journal-title":"Arch Ophthalmol"},{"key":"2195_CR66","first-page":"2499","volume":"14","author":"JD Akula","year":"2008","unstructured":"Akula JD, Mocko JA, Benador IY et al (2008) The neurovascular relation in oxygen-induced retinopathy. Mol Vis 14:2499\u20132508","journal-title":"Mol Vis"},{"key":"2195_CR67","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1167\/iovs.07-0204","volume":"48","author":"JD Akula","year":"2007","unstructured":"Akula JD, Hansen RM, Martinez-Perez ME, Fulton AB (2007) Rod photoreceptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest Ophthalmol Vis Sci 48:4351\u20134359. https:\/\/doi.org\/10.1167\/iovs.07-0204","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR68","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1167\/iovs.06-0016","volume":"47","author":"K Liu","year":"2006","unstructured":"Liu K, Akula JD, Falk C et al (2006) The retinal vasculature and function of the neural retina in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 47:2639\u20132647. https:\/\/doi.org\/10.1167\/iovs.06-0016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR69","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/s0161-6420(93)31664-7","volume":"100","author":"DG Hunter","year":"1993","unstructured":"Hunter DG, Repka MX (1993) Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study Ophthalmology 100:238\u2013244. https:\/\/doi.org\/10.1016\/s0161-6420(93)31664-7","journal-title":"A randomized study Ophthalmology"},{"key":"2195_CR70","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0161-6420(91)32247-4","volume":"98","author":"JA McNamara","year":"1991","unstructured":"McNamara JA, Tasman W, Brown GC, Federman JL (1991) Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology 98:576\u2013580. https:\/\/doi.org\/10.1016\/s0161-6420(91)32247-4","journal-title":"Ophthalmology"},{"key":"2195_CR71","doi-asserted-by":"publisher","unstructured":"Ng EYJ, Connolly BP, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928\u2013934; discussion 935. https:\/\/doi.org\/10.1016\/s0161-6420(01)01017-x","DOI":"10.1016\/s0161-6420(01)01017-x"},{"key":"2195_CR72","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/s0161-6420(01)01015-6","volume":"109","author":"BP Connolly","year":"2002","unstructured":"Connolly BP, Ng EYJ, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome Ophthalmology 109:936\u2013941. https:\/\/doi.org\/10.1016\/s0161-6420(01)01015-6","journal-title":"Refractive outcome Ophthalmology"},{"key":"2195_CR73","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/s0002-9394(14)71402-3","volume":"116","author":"A Capone","year":"1993","unstructured":"Capone A, Diaz-Rohena R, Sternberg P et al (1993) Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 116:444\u2013450. https:\/\/doi.org\/10.1016\/s0002-9394(14)71402-3","journal-title":"Am J Ophthalmol"},{"key":"2195_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preteyeres.2017.09.002","volume":"62","author":"T Chan-Ling","year":"2018","unstructured":"Chan-Ling T, Gole GA, Quinn GE et al (2018) Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. Prog Retin Eye Res 62:77\u2013119. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.09.002","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR75","doi-asserted-by":"publisher","first-page":"11946","DOI":"10.1073\/pnas.182296499","volume":"99","author":"K Jin","year":"2002","unstructured":"Jin K, Zhu Y, Sun Y et al (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 99:11946\u201311950. https:\/\/doi.org\/10.1073\/pnas.182296499","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2195_CR76","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB et al (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331\u2013371. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.05.001","journal-title":"Prog Retin Eye Res"},{"key":"2195_CR77","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","volume":"115","author":"K Sonmez","year":"2008","unstructured":"Sonmez K, Drenser KA, Capone A, Trese MT (2008) Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115:1065-1070.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2007.08.050","journal-title":"Ophthalmology"},{"key":"2195_CR78","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","volume":"114","author":"EA Pierce","year":"1996","unstructured":"Pierce EA, Foley ED, Smith LE (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114:1219\u20131228. https:\/\/doi.org\/10.1001\/archopht.1996.01100140419009","journal-title":"Arch Ophthalmol"},{"key":"2195_CR79","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1073\/pnas.92.3.905","volume":"92","author":"EA Pierce","year":"1995","unstructured":"Pierce EA, Avery RL, Foley ED et al (1995) Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92:905\u2013909. https:\/\/doi.org\/10.1073\/pnas.92.3.905","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2195_CR80","first-page":"290","volume":"37","author":"J Stone","year":"1996","unstructured":"Stone J, Chan-Ling T, Pe\u2019er J et al (1996) Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 37:290\u2013299","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR81","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.survophthal.2021.02.012","volume":"66","author":"H Tan","year":"2021","unstructured":"Tan H, Blasco P, Lewis T et al (2021) Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity. Surv Ophthalmol 66:877\u2013891. https:\/\/doi.org\/10.1016\/j.survophthal.2021.02.012","journal-title":"Surv Ophthalmol"},{"key":"2195_CR82","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394:1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"2195_CR83","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00018-021-04111-2","volume":"79","author":"C Dai","year":"2022","unstructured":"Dai C, Waduge P, Ji L et al (2022) Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Cell Mol Life Sci 79:63. https:\/\/doi.org\/10.1007\/s00018-021-04111-2","journal-title":"Cell Mol Life Sci"},{"key":"2195_CR84","doi-asserted-by":"publisher","unstructured":"Ji L, Waduge P, Hao L et al (2022) Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.\u00a0FASEB J 36:e22106.\u00a0https:\/\/doi.org\/10.1096\/fj.202101085RR","DOI":"10.1096\/fj.202101085RR"},{"key":"2195_CR85","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1167\/iovs.13-13397","volume":"55","author":"CC Tokunaga","year":"2014","unstructured":"Tokunaga CC, Mitton KP, Dailey W et al (2014) Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 55:1884\u20131892. https:\/\/doi.org\/10.1167\/iovs.13-13397","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR86","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10456-019-09662-4","volume":"22","author":"F Tang","year":"2019","unstructured":"Tang F, LeBlanc ME, Wang W et al (2019) Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Angiogenesis 22:369\u2013382. https:\/\/doi.org\/10.1007\/s10456-019-09662-4","journal-title":"Angiogenesis"},{"key":"2195_CR87","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1167\/iovs.10-6798","volume":"52","author":"GA Lutty","year":"2011","unstructured":"Lutty GA, McLeod DS, Bhutto I, Wiegand SJ (2011) Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 52:4039\u20134047. https:\/\/doi.org\/10.1167\/iovs.10-6798","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR88","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002414R","volume":"35","author":"Y Ichiyama","year":"2021","unstructured":"Ichiyama Y, Obata S, Saishin Y et al (2021) The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity. FASEB J 35:e21390. https:\/\/doi.org\/10.1096\/fj.202002414R","journal-title":"FASEB J"},{"key":"2195_CR89","doi-asserted-by":"publisher","unstructured":"Zimna A, Kurpisz M (2015) Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: Applications and therapies. Biomed Res Int 2015:549412. https:\/\/doi.org\/10.1155\/2015\/549412","DOI":"10.1155\/2015\/549412"},{"key":"2195_CR90","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1002\/jcp.26805","volume":"233","author":"C Befani","year":"2018","unstructured":"Befani C, Liakos P (2018) The role of hypoxia-inducible factor-2 alpha in angiogenesis. J Cell Physiol 233:9087\u20139098. https:\/\/doi.org\/10.1002\/jcp.26805","journal-title":"J Cell Physiol"},{"key":"2195_CR91","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/cas.13483","volume":"109","author":"S Koyasu","year":"2018","unstructured":"Koyasu S, Kobayashi M, Goto Y et al (2018) Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge. Cancer Sci 109:560\u2013571. https:\/\/doi.org\/10.1111\/cas.13483","journal-title":"Cancer Sci"},{"key":"2195_CR92","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1167\/iovs.10-6222","volume":"52","author":"C Caprara","year":"2011","unstructured":"Caprara C, Thiersch M, Lange C et al (2011) HIF1A is essential for the development of the intermediate plexus of the retinal vasculature. Invest Ophthalmol Vis Sci 52:2109\u20132117. https:\/\/doi.org\/10.1167\/iovs.10-6222","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR93","doi-asserted-by":"publisher","unstructured":"Cristante E, Liyanage SE, Sampson RD et al (2018) Late neuroprogenitors contribute to normal retinal vascular development in a Hif2a-dependent manner. Development 145:dev157511. https:\/\/doi.org\/10.1242\/dev.157511","DOI":"10.1242\/dev.157511"},{"key":"2195_CR94","doi-asserted-by":"publisher","unstructured":"Zhang J, Qin Y, Martinez M et al (2021) HIF-1\u03b1 and HIF-2\u03b1 redundantly promote retinal neovascularization in patients with ischemic retinal disease. J Clin Invest 131:e139202. https:\/\/doi.org\/10.1172\/JCI139202","DOI":"10.1172\/JCI139202"},{"key":"2195_CR95","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/emboj\/cdg117","volume":"22","author":"M Morita","year":"2003","unstructured":"Morita M, Ohneda O, Yamashita T et al (2003) HLF\/HIF-2\u03b1 is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22:1134\u20131146. https:\/\/doi.org\/10.1093\/emboj\/cdg117","journal-title":"EMBO J"},{"key":"2195_CR96","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3387","volume":"137","author":"JL Fang","year":"2016","unstructured":"Fang JL, Sorita A, Carey WA et al (2016) Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis. Pediatrics 137:e20153387. https:\/\/doi.org\/10.1542\/peds.2015-3387","journal-title":"Pediatrics"},{"key":"2195_CR97","doi-asserted-by":"publisher","first-page":"19898","DOI":"10.1073\/pnas.0805817105","volume":"105","author":"JE Sears","year":"2008","unstructured":"Sears JE, Hoppe G, Ebrahem Q, Anand-Apte B (2008) Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci 105:19898\u201319903. https:\/\/doi.org\/10.1073\/pnas.0805817105","journal-title":"Proc Natl Acad Sci"},{"key":"2195_CR98","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1167\/iovs.13-12171","volume":"54","author":"G Trichonas","year":"2013","unstructured":"Trichonas G, Lee TJ, Hoppe G et al (2013) Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy in the rat 50\/10 model. Invest Ophthalmol Vis Sci 54:4919\u20134926. https:\/\/doi.org\/10.1167\/iovs.13-12171","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2195_CR99","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.ajpath.2014.02.017","volume":"184","author":"G Hoppe","year":"2014","unstructured":"Hoppe G, Lee TJ, Yoon S et al (2014) Inducing a Visceral Organ to Protect a Peripheral Capillary Bed. Am J Pathol 184:1890\u20131899. https:\/\/doi.org\/10.1016\/j.ajpath.2014.02.017","journal-title":"Am J Pathol"},{"key":"2195_CR100","doi-asserted-by":"publisher","first-page":"E2516","DOI":"10.1073\/pnas.1523005113","volume":"113","author":"G Hoppe","year":"2016","unstructured":"Hoppe G, Yoon S, Gopalan B et al (2016) Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. Proc Natl Acad Sci USA 113:E2516\u2013E2525. https:\/\/doi.org\/10.1073\/pnas.1523005113","journal-title":"Proc Natl Acad Sci USA"},{"key":"2195_CR101","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1907423","volume":"382","author":"SE Juul","year":"2020","unstructured":"Juul SE, Comstock BA, Wadhawan R et al (2020) A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. N Engl J Med 382:233\u2013243. https:\/\/doi.org\/10.1056\/NEJMoa1907423","journal-title":"N Engl J Med"},{"key":"2195_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.517207","volume":"8","author":"S Horsch","year":"2020","unstructured":"Horsch S, Parodi A, Hallberg B et al (2020) Randomized Control Trial of Postnatal rhIGF-1\/rhIGFBP-3 Replacement in Preterm Infants: Post-hoc Analysis of Its Effect on Brain Injury. Front Pediatr 8:517207. https:\/\/doi.org\/10.3389\/fped.2020.517207","journal-title":"Front Pediatr"},{"key":"2195_CR103","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0161-6420(85)33913-1","volume":"92","author":"DB Schaffer","year":"1985","unstructured":"Schaffer DB, Johnson L, Quinn GE et al (1985) Vitamin E and Retinopathy of Prematurity. Ophthalmology 92:1005\u20131011. https:\/\/doi.org\/10.1016\/S0161-6420(85)33913-1","journal-title":"Ophthalmology"},{"key":"2195_CR104","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1097\/IAE.0000000000002543","volume":"40","author":"H Sun","year":"2020","unstructured":"Sun H, Cheng R, Wang Z (2020) EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS. Retina 40:1176\u20131184. https:\/\/doi.org\/10.1097\/IAE.0000000000002543","journal-title":"Retina"},{"key":"2195_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106100","volume":"177","author":"FD Firouzabadi","year":"2022","unstructured":"Firouzabadi FD, Shab-Bidar S, Jayedi A (2022) The effects of omega-3 polyunsaturated fatty acids supplementation in pregnancy, lactation, and infancy: An umbrella review of meta-analyses of randomized trials. Pharmacol Res 177:106100. https:\/\/doi.org\/10.1016\/j.phrs.2022.106100","journal-title":"Pharmacol Res"},{"key":"2195_CR106","doi-asserted-by":"publisher","unstructured":"Filippi L, Cavallaro G, Berti E et al (2019) Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study. Front Pediatr 7:180. https:\/\/doi.org\/10.3389\/fped.2019.00180","DOI":"10.3389\/fped.2019.00180"},{"key":"2195_CR107","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jpeds.2018.10.033","volume":"206","author":"D Ley","year":"2019","unstructured":"Ley D, Hallberg B, Hansen-Pupp I et al (2019) rhIGF-1\/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial. J Pediatr 206:56-65.e8. https:\/\/doi.org\/10.1016\/j.jpeds.2018.10.033","journal-title":"J Pediatr"},{"key":"2195_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.631673","volume":"9","author":"HB Kong","year":"2021","unstructured":"Kong HB, Zheng GY, He BM et al (2021) Clinical Efficacy and Safety of Propranolol in the Prevention and Treatment of Retinopathy of Prematurity: A Meta-Analysis of Randomized Controlled Trials. Front Pediatr 9:631673. https:\/\/doi.org\/10.3389\/fped.2021.631673","journal-title":"Front Pediatr"},{"key":"2195_CR109","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","volume":"163","author":"L Filippi","year":"2013","unstructured":"Filippi L, Cavallaro G, Bagnoli P et al (2013) Oral Propranolol for Retinopathy of Prematurity: Risks, Safety Concerns, and Perspectives. J Pediatr 163:1570-1577.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2013.07.049","journal-title":"J Pediatr"},{"key":"2195_CR110","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00018-017-2635-5","volume":"75","author":"W Li","year":"2018","unstructured":"Li W, Webster KA, LeBlanc ME, Tian H (2018) Secretogranin III: a diabetic retinopathy-selective angiogenic factor. Cell Mol Life Sci 75:635\u2013647. https:\/\/doi.org\/10.1007\/s00018-017-2635-5","journal-title":"Cell Mol Life Sci"},{"key":"2195_CR111","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/j.1460-2075.1990.tb08123.x","volume":"9","author":"DM Kingsley","year":"1990","unstructured":"Kingsley DM, Rinchik EM, Russell LB et al (1990) Genetic ablation of a mouse gene expressed specifically in brain. EMBO J 9:395\u2013399","journal-title":"EMBO J"},{"key":"2195_CR112","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1084\/jem.20161802","volume":"214","author":"ME LeBlanc","year":"2017","unstructured":"LeBlanc ME, Wang W, Chen X et al (2017) Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med 214:1029\u20131047. https:\/\/doi.org\/10.1084\/jem.20161802","journal-title":"J Exp Med"},{"key":"2195_CR113","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.exer.2019.03.009","volume":"182","author":"X Rong","year":"2019","unstructured":"Rong X, Tian H, Yang L, Li W (2019) Function-first ligandomics for ocular vascular research and drug target discovery. Exp Eye Res 182:57\u201364. https:\/\/doi.org\/10.1016\/j.exer.2019.03.009","journal-title":"Exp Eye Res"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-022-02195-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-022-02195-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-022-02195-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T09:04:11Z","timestamp":1654247051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-022-02195-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1007\/s00109-022-02195-2","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"WL is the shareholder of Everglades Biopharma, LLC, and LigandomicsRx, LLC. WL is an inventor of issued and pending patents. The remaining authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}